首页 > 最新文献

International Journal of Breast Cancer最新文献

英文 中文
Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients. 新辅助化疗会缩短乳腺癌患者的 cfDNA 端粒长度
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-11-14 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6117394
İrem Peker Eyüboğlu, Sinan Koca, Betül Çelik, Gökçe Güllü Amuran, M Ümit Uğurlu, Özkan Alan, Tuğba Akın Telli, Perran Fulden Yumuk, Mustafa Akkiprik

Introduction: Cancer is a genetic disease that affects people worldwide, and breast cancer is the most common cancer in women. Studies have been conducted on molecular parameters to predict tumor behavior and develop therapeutic strategies. Telomeres, which are at the end of chromosomes, have been studied for their relationship with breast cancer, but more research is needed to understand their role in the disease. Circulating-free DNA (cfDNA) is DNA that is free in the bloodstream and is considered a promising target for early cancer detection, treatment response monitoring, and prognosis assessment. This study is aimed at comparing cfDNA telomere length of breast cancer patients and healthy individuals and analyzing the impact of neoadjuvant chemotherapy on telomere length in cfDNA. Materials and Methods: Blood samples were collected from 33 breast cancer patients undergoing neoadjuvant chemotherapy before and after treatment. The quantitative PCR method is used to measure the average telomere lengths. Results: This study found that the telomere length of cfDNA in breast cancer patients before and after treatment is significantly shorter than in the control group. Neoadjuvant chemotherapy is found to shorten the cfDNA telomere length, especially in the treatment-responsive group. Conclusion: Our study suggests that telomere length in cfDNA may be a useful biomarker for predicting therapy response and possible reoccurrence of the disease in breast cancer patients.

导言癌症是一种遗传性疾病,影响着全世界的人们,而乳腺癌是女性最常见的癌症。人们对分子参数进行了研究,以预测肿瘤行为并制定治疗策略。位于染色体末端的端粒与乳腺癌的关系已得到研究,但还需要更多的研究来了解端粒在乳腺癌中的作用。循环游离DNA(cfDNA)是游离在血液中的DNA,被认为是早期癌症检测、治疗反应监测和预后评估的理想靶点。本研究旨在比较乳腺癌患者和健康人的 cfDNA 端粒长度,并分析新辅助化疗对 cfDNA 端粒长度的影响。材料和方法:采集33名接受新辅助化疗的乳腺癌患者治疗前后的血液样本。采用定量 PCR 方法测量端粒的平均长度。结果:本研究发现,乳腺癌患者在治疗前后的 cfDNA 端粒长度明显短于对照组。发现新辅助化疗会缩短cfDNA端粒长度,尤其是在治疗反应组。结论我们的研究表明,cfDNA 中的端粒长度可能是预测乳腺癌患者治疗反应和可能复发的有用生物标志物。
{"title":"Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients.","authors":"İrem Peker Eyüboğlu, Sinan Koca, Betül Çelik, Gökçe Güllü Amuran, M Ümit Uğurlu, Özkan Alan, Tuğba Akın Telli, Perran Fulden Yumuk, Mustafa Akkiprik","doi":"10.1155/2024/6117394","DOIUrl":"10.1155/2024/6117394","url":null,"abstract":"<p><p><b>Introduction:</b> Cancer is a genetic disease that affects people worldwide, and breast cancer is the most common cancer in women. Studies have been conducted on molecular parameters to predict tumor behavior and develop therapeutic strategies. Telomeres, which are at the end of chromosomes, have been studied for their relationship with breast cancer, but more research is needed to understand their role in the disease. Circulating-free DNA (cfDNA) is DNA that is free in the bloodstream and is considered a promising target for early cancer detection, treatment response monitoring, and prognosis assessment. This study is aimed at comparing cfDNA telomere length of breast cancer patients and healthy individuals and analyzing the impact of neoadjuvant chemotherapy on telomere length in cfDNA. <b>Materials and Methods:</b> Blood samples were collected from 33 breast cancer patients undergoing neoadjuvant chemotherapy before and after treatment. The quantitative PCR method is used to measure the average telomere lengths. <b>Results:</b> This study found that the telomere length of cfDNA in breast cancer patients before and after treatment is significantly shorter than in the control group. Neoadjuvant chemotherapy is found to shorten the cfDNA telomere length, especially in the treatment-responsive group. <b>Conclusion:</b> Our study suggests that telomere length in cfDNA may be a useful biomarker for predicting therapy response and possible reoccurrence of the disease in breast cancer patients.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"6117394"},"PeriodicalIF":1.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes From Real-World Data on Intraoperative Electronic Radiotherapy for the Treatment of Early-Stage Breast Cancer: Long-Term Recurrence and Survival Outcomes From a Single Center. 术中电子放疗治疗早期乳腺癌的真实世界数据结果:来自单一中心的长期复发和生存结果。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-11-14 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6207762
Dolores De la Mata, Bernardino Gabriel Santiago-Concha, Juan Enrique Bargalló-Rocha, Carlos Daniel Robles-Vidal, Daniella Gómez-Pue, Gerardo Castorena-Rojí, José Hinojosa-Gómez, Fabiola Flores-Vázquez, Mónika Blake-Cerda, Mario Enriquez-Barrera, Antonio Maffuz-Aziz

Purpose: This study is aimed at investigating the 10-year outcomes of intraoperative radiotherapy (IORT) in Mexican women with early breast cancer (EBC) treated at the Centro Medico ABC, Mexico City. Methods: A cohort study included women with early-stage invasive ductal carcinoma aged ≥ 45 years without prior oncologic treatment, tumor size ≤ 3.5 cm, cN0M0, positive hormone receptors, margins ≥ 2 mm, negative sentinel lymph nodes, and no extensive lymphovascular invasion. IORT was administered at 20 Gy for 20-30 min after a lumpectomy. Follow-up extended over 10 years and included clinical examinations every 6 months for the first 18 months, followed by annual mammograms and conventional examinations. Patients out of the criteria were excluded from this study because they were referred for additional surgery and/or whole-breast radiation therapy. Results: The study involved 238 patients with an average age of 61.1 years. The mean tumor size was 12 mm, and the percentages of lymphatic invasion, positive hormone receptors, and HER2/neu overexpression were 12.6%, 90.8%, and 2.1%, respectively. The median follow-up was 66.6 months (range: 1-126 months), and the overall survival and mastectomy-free rate reached 95.7% and 90%, respectively. Thirteen patients showed side effects; four recurrences were recorded, of which 50% were out-field relapses. The 5-year Kaplan-Meier probability of local relapses, mastectomy-free, and overall survival reached 97.5%, 100%, and 98%, respectively. Conclusions: This is the first 10-year report about the effect of IORT on Mexican women with EBC in the early stages. Strict adherence to the selection criteria in this study resulted in low rates of side effects, mortality, and local recurrences, demonstrating that IORT is an effective treatment alternative for patients with EBC. Studies with a longer follow-up period should be performed, as recurrences can occur in the long term.

目的:本研究旨在调查在墨西哥城 ABC 医学中心接受早期乳腺癌 (EBC) 治疗的墨西哥妇女术中放疗 (IORT) 的 10 年疗效。研究方法:一项队列研究纳入了年龄≥45岁、未接受过肿瘤治疗、肿瘤大小≤3.5厘米、cN0M0、激素受体阳性、边缘≥2毫米、前哨淋巴结阴性、无广泛淋巴管侵犯的早期浸润性导管癌女性患者。IORT在肿块切除术后进行,每次20 Gy,20-30分钟。随访时间长达10年,包括前18个月每6个月进行一次临床检查,之后每年进行一次乳房X光检查和常规检查。本研究排除了不符合标准的患者,因为他们被转诊接受了额外的手术和/或全乳放射治疗。研究结果研究共涉及 238 名患者,平均年龄为 61.1 岁。肿瘤平均大小为 12 毫米,淋巴侵犯、激素受体阳性和 HER2/neu 过表达的比例分别为 12.6%、90.8% 和 2.1%。中位随访时间为 66.6 个月(范围:1-126 个月),总生存率和无乳腺切除率分别达到 95.7% 和 90%。13名患者出现了副作用;4例复发,其中50%为外地复发。局部复发、无乳房切除和总生存的5年Kaplan-Meier概率分别达到97.5%、100%和98%。结论:这是第一份关于 IORT 对早期 EBC 墨西哥女性患者影响的 10 年报告。该研究严格遵守选择标准,副作用、死亡率和局部复发率都很低,这表明 IORT 是治疗 EBC 患者的有效替代方法。由于长期治疗可能会出现复发,因此应进行更长时间的随访研究。
{"title":"Outcomes From Real-World Data on Intraoperative Electronic Radiotherapy for the Treatment of Early-Stage Breast Cancer: Long-Term Recurrence and Survival Outcomes From a Single Center.","authors":"Dolores De la Mata, Bernardino Gabriel Santiago-Concha, Juan Enrique Bargalló-Rocha, Carlos Daniel Robles-Vidal, Daniella Gómez-Pue, Gerardo Castorena-Rojí, José Hinojosa-Gómez, Fabiola Flores-Vázquez, Mónika Blake-Cerda, Mario Enriquez-Barrera, Antonio Maffuz-Aziz","doi":"10.1155/2024/6207762","DOIUrl":"10.1155/2024/6207762","url":null,"abstract":"<p><p><b>Purpose:</b> This study is aimed at investigating the 10-year outcomes of intraoperative radiotherapy (IORT) in Mexican women with early breast cancer (EBC) treated at the Centro Medico ABC, Mexico City. <b>Methods:</b> A cohort study included women with early-stage invasive ductal carcinoma aged ≥ 45 years without prior oncologic treatment, tumor size ≤ 3.5 cm, cN0M0, positive hormone receptors, margins ≥ 2 mm, negative sentinel lymph nodes, and no extensive lymphovascular invasion. IORT was administered at 20 Gy for 20-30 min after a lumpectomy. Follow-up extended over 10 years and included clinical examinations every 6 months for the first 18 months, followed by annual mammograms and conventional examinations. Patients out of the criteria were excluded from this study because they were referred for additional surgery and/or whole-breast radiation therapy. <b>Results:</b> The study involved 238 patients with an average age of 61.1 years. The mean tumor size was 12 mm, and the percentages of lymphatic invasion, positive hormone receptors, and HER2/neu overexpression were 12.6%, 90.8%, and 2.1%, respectively. The median follow-up was 66.6 months (range: 1-126 months), and the overall survival and mastectomy-free rate reached 95.7% and 90%, respectively. Thirteen patients showed side effects; four recurrences were recorded, of which 50% were out-field relapses. The 5-year Kaplan-Meier probability of local relapses, mastectomy-free, and overall survival reached 97.5%, 100%, and 98%, respectively. <b>Conclusions:</b> This is the first 10-year report about the effect of IORT on Mexican women with EBC in the early stages. Strict adherence to the selection criteria in this study resulted in low rates of side effects, mortality, and local recurrences, demonstrating that IORT is an effective treatment alternative for patients with EBC. Studies with a longer follow-up period should be performed, as recurrences can occur in the long term.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"6207762"},"PeriodicalIF":1.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Culturally Appropriate Text Messaging Platform for Improving Breast Cancer Screening Uptake Among Ghanaian Women in Metropolitan Areas. 开发与文化相适应的短信平台,提高大都市地区加纳妇女的乳腺癌筛查率。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-10-24 eCollection Date: 2024-01-01 DOI: 10.1155/2024/5587515
Ransford Paul Selasi Sefenu, Adolphina Addoley Addo-Lartey, Harriet Affran Bonful, Adanna Nwameme, Timothy Agandah Abagre, Adolf Kofi Awua, Kofi Agyabeng, Kwabena Oteng Birimpong, Nii Armah Adu-Aryee, Florence Dedey, Richard Mawuena Kofi Adanu, Kolawole Stephen Okuyemi

Objective: Early detection through screening could improve breast cancer (BC) outcomes in sub-Saharan Africa (SSA). We explored women's preferences for BC-related mobile health text messaging, described the development of a mobile-health text messaging platform, and examined the enablers and barriers to BC screening. Methods: A concurrent mixed-method study of women aged 40-59 years was conducted. Four essential actions were carried out: (i) a baseline survey of 130 women, (ii) five focus group discussions (FGDs), (iii) a stakeholder meeting with BC research and clinical treatment specialists, and (iv) text message pretesting. The survey and FGD findings were used to create a culturally appropriate SMS platform for BC screening. Results: Thirty-five text messages were developed and evaluated with the following communication goals in mind: 15 addressed BC awareness, six emphasized the importance of early detection, five alleviated anxieties as a barrier to BC screening, seven encouraged women to prioritize their health, and three indicated screening locations and costs. The majority (92.6%) of survey respondents who had heard of mammography (54/130) said screening was necessary. Fear of the screening procedure, receiving a positive diagnosis, and other testing-related worries (40.7%) were identified as potential barriers to BC screening, along with low income (18.5%), a lack of BC-related indicators (9.3%), insufficient breast awareness education (9.3%), and time restrictions (7.4%). The presence of BC-related symptoms (27.8%), breast awareness education (24.1%), and doctor's advice (16.7%) were all potential facilitators of BC screening uptake. The majority of FGD participants favored brief texts, with 42.3% preferring one text message per day. Conclusion: Several factors limit women from accessing BC screening services; nevertheless, specific barriers such as a lack of BC education, time constraints, and disease fears can be successfully targeted through SMS messaging interventions to encourage women to use BC screening programs.

目的:通过筛查及早发现可改善撒哈拉以南非洲地区(SSA)的乳腺癌(BC)治疗效果。我们探讨了妇女对与乳腺癌相关的移动健康短信的偏好,介绍了移动健康短信平台的开发情况,并研究了乳腺癌筛查的促进因素和障碍。研究方法对 40-59 岁的女性进行了一项同步混合方法研究。开展了四项基本行动:(i) 对 130 名妇女进行基线调查,(ii) 进行五次焦点小组讨论 (FGD),(iii) 与 BC 研究和临床治疗专家举行利益相关者会议,以及 (iv) 进行短信预试。调查和 FGD 的结果被用于创建一个适合不同文化背景的 BC 筛查短信平台。结果开发并评估了 35 条短信,其传播目标如下:其中 15 条涉及对 BC 的认识,6 条强调了早期发现的重要性,5 条缓解了作为 BC 筛查障碍的焦虑,7 条鼓励妇女优先考虑自己的健康,3 条指出了筛查地点和费用。大多数(92.6%)听说过乳房 X 线照相术的受访者(54/130)认为筛查是必要的。对筛查过程的恐惧、得到阳性诊断以及其他与检查相关的担忧(40.7%)被认为是乳腺增生筛查的潜在障碍,此外还有低收入(18.5%)、缺乏乳腺增生相关指标(9.3%)、乳腺知识教育不足(9.3%)以及时间限制(7.4%)。出现乳腺癌相关症状(27.8%)、乳腺知识教育(24.1%)和医生建议(16.7%)都是接受乳腺癌筛查的潜在促进因素。大多数 FGD 参与者喜欢简短的短信,42.3% 的人喜欢每天一条短信。结论有几个因素限制了妇女接受子宫颈癌筛查服务;然而,一些特定的障碍,如缺乏子宫颈癌教育、时间限制和对疾病的恐惧等,都可以通过短信干预成功地解决,以鼓励妇女使用子宫颈癌筛查项目。
{"title":"Development of a Culturally Appropriate Text Messaging Platform for Improving Breast Cancer Screening Uptake Among Ghanaian Women in Metropolitan Areas.","authors":"Ransford Paul Selasi Sefenu, Adolphina Addoley Addo-Lartey, Harriet Affran Bonful, Adanna Nwameme, Timothy Agandah Abagre, Adolf Kofi Awua, Kofi Agyabeng, Kwabena Oteng Birimpong, Nii Armah Adu-Aryee, Florence Dedey, Richard Mawuena Kofi Adanu, Kolawole Stephen Okuyemi","doi":"10.1155/2024/5587515","DOIUrl":"10.1155/2024/5587515","url":null,"abstract":"<p><p><b>Objective:</b> Early detection through screening could improve breast cancer (BC) outcomes in sub-Saharan Africa (SSA). We explored women's preferences for BC-related mobile health text messaging, described the development of a mobile-health text messaging platform, and examined the enablers and barriers to BC screening. <b>Methods:</b> A concurrent mixed-method study of women aged 40-59 years was conducted. Four essential actions were carried out: (i) a baseline survey of 130 women, (ii) five focus group discussions (FGDs), (iii) a stakeholder meeting with BC research and clinical treatment specialists, and (iv) text message pretesting. The survey and FGD findings were used to create a culturally appropriate SMS platform for BC screening. <b>Results:</b> Thirty-five text messages were developed and evaluated with the following communication goals in mind: 15 addressed BC awareness, six emphasized the importance of early detection, five alleviated anxieties as a barrier to BC screening, seven encouraged women to prioritize their health, and three indicated screening locations and costs. The majority (92.6%) of survey respondents who had heard of mammography (54/130) said screening was necessary. Fear of the screening procedure, receiving a positive diagnosis, and other testing-related worries (40.7%) were identified as potential barriers to BC screening, along with low income (18.5%), a lack of BC-related indicators (9.3%), insufficient breast awareness education (9.3%), and time restrictions (7.4%). The presence of BC-related symptoms (27.8%), breast awareness education (24.1%), and doctor's advice (16.7%) were all potential facilitators of BC screening uptake. The majority of FGD participants favored brief texts, with 42.3% preferring one text message per day. <b>Conclusion:</b> Several factors limit women from accessing BC screening services; nevertheless, specific barriers such as a lack of BC education, time constraints, and disease fears can be successfully targeted through SMS messaging interventions to encourage women to use BC screening programs.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"5587515"},"PeriodicalIF":1.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential Therapeutic Targets in Triple-Negative Breast Cancer Based on Gene Regulatory Network Analysis: A Comprehensive Systems Biology Approach. 基于基因调控网络分析的三阴性乳腺癌潜在治疗靶点:一种全面的系统生物学方法
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-10-22 eCollection Date: 2024-01-01 DOI: 10.1155/2024/8796102
Maryam Ahmadi, Neda Barkhoda, Aida Alizamir, Amir Taherkhani

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. This study is aimed at identifying potential therapeutic targets in TNBC using gene regulatory network analysis and a system biology approach. Methods: The GSE38959 dataset was reanalyzed to identify differentially expressed genes (DEGs) in TNBC tissues compared to normal breast samples. Protein-protein interaction networks were constructed, and hub genes were identified. Survival analysis was performed using GEPIA2. Gene regulatory networks were built to identify upstream regulators. Cross-platform verification was conducted using an independent RNA-seq dataset (GSE58135). Expression analysis of prognostic markers in TNBC versus non-TNBC samples was performed using bc-GenExMiner. Results: A total of 943 DEGs were identified in TNBC tissues. CHEK1 and PLK1 were identified as central hub genes, with overexpression correlating with poor prognosis. GABPB1 was identified as the most influential upstream regulator of CHEK1 and PLK1 through gene regulatory network analysis, while JUN exhibited the most interactions among regulators. A total of 302 consistently modulated genes were confirmed through cross-platform verification. The overexpression of CHEK1 and PLK1 in TNBC compared to non-TNBC samples was validated by expression analysis. Conclusion: This study provides insights into the molecular mechanisms of TNBC and suggests CHEK1, PLK1, and their upstream regulators as potential therapeutic targets for TNBC treatment.

背景:三阴性乳腺癌(TNBC三阴性乳腺癌(TNBC)是一种侵袭性亚型癌症,治疗方案有限。本研究旨在利用基因调控网络分析和系统生物学方法确定 TNBC 的潜在治疗靶点。研究方法对 GSE38959 数据集进行重新分析,以确定 TNBC 组织中与正常乳腺样本相比有差异表达的基因(DEGs)。构建了蛋白质-蛋白质相互作用网络,并确定了中心基因。使用 GEPIA2 进行了生存分析。构建基因调控网络以确定上游调控因子。利用独立的 RNA-seq 数据集(GSE58135)进行了跨平台验证。使用 bc-GenExMiner 对 TNBC 与非 TNBC 样本中的预后标志物进行了表达分析。结果在 TNBC 组织中共鉴定出 943 个 DEGs。CHEK1和PLK1被确定为中心枢纽基因,其过表达与不良预后相关。通过基因调控网络分析,发现GABPB1是对CHEK1和PLK1影响最大的上游调控因子,而JUN则是调控因子间相互作用最多的基因。通过跨平台验证,共确认了302个一致调控的基因。通过表达分析验证了与非 TNBC 样本相比,CHEK1 和 PLK1 在 TNBC 中的过度表达。结论本研究揭示了 TNBC 的分子机制,并建议将 CHEK1、PLK1 及其上游调控因子作为 TNBC 治疗的潜在靶点。
{"title":"Potential Therapeutic Targets in Triple-Negative Breast Cancer Based on Gene Regulatory Network Analysis: A Comprehensive Systems Biology Approach.","authors":"Maryam Ahmadi, Neda Barkhoda, Aida Alizamir, Amir Taherkhani","doi":"10.1155/2024/8796102","DOIUrl":"https://doi.org/10.1155/2024/8796102","url":null,"abstract":"<p><p><b>Background:</b> Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. This study is aimed at identifying potential therapeutic targets in TNBC using gene regulatory network analysis and a system biology approach. <b>Methods</b>: The GSE38959 dataset was reanalyzed to identify differentially expressed genes (DEGs) in TNBC tissues compared to normal breast samples. Protein-protein interaction networks were constructed, and hub genes were identified. Survival analysis was performed using GEPIA2. Gene regulatory networks were built to identify upstream regulators. Cross-platform verification was conducted using an independent RNA-seq dataset (GSE58135). Expression analysis of prognostic markers in TNBC versus non-TNBC samples was performed using bc-GenExMiner. <b>Results:</b> A total of 943 DEGs were identified in TNBC tissues. CHEK1 and PLK1 were identified as central hub genes, with overexpression correlating with poor prognosis. GABPB1 was identified as the most influential upstream regulator of CHEK1 and PLK1 through gene regulatory network analysis, while JUN exhibited the most interactions among regulators. A total of 302 consistently modulated genes were confirmed through cross-platform verification. The overexpression of CHEK1 and PLK1 in TNBC compared to non-TNBC samples was validated by expression analysis. <b>Conclusion</b>: This study provides insights into the molecular mechanisms of TNBC and suggests CHEK1, PLK1, and their upstream regulators as potential therapeutic targets for TNBC treatment.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"8796102"},"PeriodicalIF":1.6,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical-Pathological and Survival Biological Effects. 墨西哥 HER-2 过度表达乳腺癌患者外显子 9(E545K 和 E542K)和 20(H1047R)上的 PI3K 基因突变概况及其对临床病理和生存生物学影响的相关性。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.1155/2024/9058033
T Nieto-Coronel, Ortega-Gómez Alette, R Yacab, E A Fernández-Figueroa, C Lopez-Camarillo, L Marchat, H Astudillo-de la Vega, E Ruiz-Garcia

Background: Trastuzumab resistance is associated with overexpressing the human epidermal growth factor receptor 2 (HER-2), which results from the altered phosphoinositide 3-kinase (PI3K) pathway in breast cancer patients. Objective: We quantified the frequency of PI3K enzyme single and double-point mutations in Mexican patients with HER-2 overexpressing breast cancer and its association with clinical-pathological variables. Methods: We embedded HER-2 breast samples in paraffin from 60 patients, extracted their DNA, and evaluated PI3K mutations in 49 HER-2-positive breast tumors. We focused on mutations for one exon 20 (H1047R) and two exon 9 PI3K (E545K, E542K) hotspots and characterized them as single and double-point mutations. The mean patient follow-up was 86 months. Results: Of 49 patients who tested positive for HER-2 breast cancer, 14.28% showed mutations in PI3K, 71.42% single-point, and 28.56% double-point mutations. We found single-point mutations in H1047R (42.85%) and E545K (28.57%). Only two patients exhibited double-point mutations: one in E542K/E545K and another in H1047R/E545K (14.28% each). Although we observed lower survival in patients with mutations in PI3K, we did not find a significant association between these factors (p = 0.191). However, single and double-point mutations in PI3K were significantly associated with the clinical stages of diagnosis and tumor size (p = 0.027 and p = 0.04, respectively). Conclusion: Single and double-point mutations in PI3K are related to tumor size and advanced clinical-pathological traits in Mexican patients with HER-2 overexpression, and future molecular studies are necessary to understand these findings.

背景:曲妥珠单抗的耐药性与人表皮生长因子受体 2(HER-2)的过度表达有关,而人表皮生长因子受体 2 的过度表达是乳腺癌患者体内磷酸肌酸 3- 激酶(PI3K)通路发生改变的结果。研究目的我们对墨西哥 HER-2 过度表达乳腺癌患者中 PI3K 酶单点和双点突变的频率及其与临床病理变量的关系进行了量化。研究方法我们将 60 例患者的 HER-2 乳腺样本包埋在石蜡中,提取其 DNA,并评估了 49 例 HER-2 阳性乳腺肿瘤中的 PI3K 基因突变。我们重点研究了一个20号外显子(H1047R)和两个9号外显子(E545K、E542K)的PI3K热点突变,并将其定性为单点和双点突变。患者的平均随访时间为 86 个月。结果在49名HER-2检测呈阳性的乳腺癌患者中,14.28%出现了PI3K突变,71.42%为单点突变,28.56%为双点突变。我们发现单点突变为 H1047R(42.85%)和 E545K(28.57%)。只有两名患者出现了双点突变:一名是E542K/E545K,另一名是H1047R/E545K(各占14.28%)。虽然我们观察到 PI3K 基因突变患者的生存率较低,但并未发现这些因素之间存在显著关联(p = 0.191)。然而,PI3K 的单点和双点突变与诊断的临床分期和肿瘤大小显著相关(分别为 p = 0.027 和 p = 0.04)。结论PI3K的单点和双点突变与HER-2过表达的墨西哥患者的肿瘤大小和晚期临床病理特征有关,未来的分子研究有必要了解这些发现。
{"title":"PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical-Pathological and Survival Biological Effects.","authors":"T Nieto-Coronel, Ortega-Gómez Alette, R Yacab, E A Fernández-Figueroa, C Lopez-Camarillo, L Marchat, H Astudillo-de la Vega, E Ruiz-Garcia","doi":"10.1155/2024/9058033","DOIUrl":"https://doi.org/10.1155/2024/9058033","url":null,"abstract":"<p><p><b>Background</b>: Trastuzumab resistance is associated with overexpressing the human epidermal growth factor receptor 2 (HER-2), which results from the altered phosphoinositide 3-kinase (PI3K) pathway in breast cancer patients. <b>Objective</b>: We quantified the frequency of PI3K enzyme single and double-point mutations in Mexican patients with HER-2 overexpressing breast cancer and its association with clinical-pathological variables. <b>Methods</b>: We embedded HER-2 breast samples in paraffin from 60 patients, extracted their DNA, and evaluated PI3K mutations in 49 HER-2-positive breast tumors. We focused on mutations for one exon 20 (H1047R) and two exon 9 PI3K (E545K, E542K) hotspots and characterized them as single and double-point mutations. The mean patient follow-up was 86 months. <b>Results</b>: Of 49 patients who tested positive for HER-2 breast cancer, 14.28% showed mutations in PI3K, 71.42% single-point, and 28.56% double-point mutations. We found single-point mutations in H1047R (42.85%) and E545K (28.57%). Only two patients exhibited double-point mutations: one in E542K/E545K and another in H1047R/E545K (14.28% each). Although we observed lower survival in patients with mutations in PI3K, we did not find a significant association between these factors (<i>p</i> = 0.191). However, single and double-point mutations in PI3K were significantly associated with the clinical stages of diagnosis and tumor size (<i>p</i> = 0.027 and <i>p</i> = 0.04, respectively). <b>Conclusion</b>: Single and double-point mutations in PI3K are related to tumor size and advanced clinical-pathological traits in Mexican patients with HER-2 overexpression, and future molecular studies are necessary to understand these findings.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"9058033"},"PeriodicalIF":1.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Uptake of Breast Cancer Screening Among Catholic Nuns in Lake Zone, Tanzania. 坦桑尼亚湖区天主教修女接受乳腺癌筛查的相关因素。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-10-12 eCollection Date: 2024-01-01 DOI: 10.1155/2024/5024392
Gotfrida Marandu, Rose Laisser, Kija Malale, Peter Rambau

Background: Breast cancer is the most common cancer among women worldwide. Breast cancer screening programs are widely promoted because of their effectiveness in the early detection of cancer. However, a significant proportion of eligible Catholic nuns in the Lake Zone of Tanzania remain underscreened. This study is aimed at investigating the factors associated with breast cancer screening uptake among Catholic nuns in Lake Zone, Tanzania. Methods: This was a cross-sectional study design among 385 catholic nuns. Simple random sampling was deployed to enrolled catholic nuns, the ODK collect v2023.2.4 was electronically used to collect data. Binary logistic regression was used to assess the factors associated with the uptake of breast cancer screening. Statistical analysis was performed using STATA 18.0, with a significance level set at a p value less than 0.05. Result: The prevalence uptake of breast cancer screening (i.e., breast self-examination, clinical examination, or mammography examination) was 64% (n = 247, 95% CI, 59.3%-68.9%). A total of 57.4% had inadequate knowledge on the uptake of breast cancer screening (n = 221, 95% CI, 52.4%-62.4%). Also, the study found that 61.3% (95% CI, 56.4%-66.2%) of Catholic Nuns have negative attitudes towards the uptake of self-breast examination among Catholic nuns. The findings revealed that 55.6% (n = 133, 95% CI, 50.6%-60.6%) and 52.7% (n = 52.7%, 95% CI, 47.7%-57.7%) of Catholic nuns negatively accept breast cancer screening and self-breast examination, respectively. Nuns aged above 60 years were less likely to not perform BCS with a COR of 0.62 (95% CI, 0.39-0.97). Also, Catholic nuns who are in the nonhealth field are more likely to not perform BCS with a COR of 1.71 (95%, 1.07-2.74). Likewise, Catholic nuns who had negative acceptability of the Self-breast examination were more likely to not perform BCS with an AOR of 1.65 (95% CI, 1.07-2.55). Conclusion: A study found a low uptake of breast cancer screening among Catholic nuns. This highlights the need for breast health intervention programs within religious congregations to address misconceptions and promote early detection.

背景:乳腺癌是全球妇女最常见的癌症。乳腺癌筛查计划因其在早期发现癌症方面的有效性而得到广泛推广。然而,坦桑尼亚湖区相当一部分符合条件的天主教修女仍未接受筛查。本研究旨在调查坦桑尼亚湖区天主教修女接受乳腺癌筛查的相关因素。研究方法这是一项横断面研究,研究对象为 385 名天主教修女。对入选的天主教修女进行简单随机抽样,使用 ODK collect v2023.2.4 电子版收集数据。采用二元逻辑回归评估与接受乳腺癌筛查相关的因素。统计分析使用 STATA 18.0 进行,显著性水平设定为 p 值小于 0.05。结果接受乳腺癌筛查(即乳房自我检查、临床检查或乳房 X 光检查)的比例为 64%(n = 247,95% CI,59.3%-68.9%)。共有 57.4% 的人对接受乳腺癌筛查的知识不足(n = 221,95% CI,52.4%-62.4%)。研究还发现,61.3%(95% CI,56.4%-66.2%)的天主教修女对天主教修女接受自我乳房检查持消极态度。研究结果显示,55.6%(n = 133,95% CI,50.6%-60.6%)和 52.7%(n = 52.7%,95% CI,47.7%-57.7%)的天主教修女对乳腺癌筛查和自我乳房检查持消极态度。60岁以上的修女不太可能不进行BCS,COR值为0.62(95% CI,0.39-0.97)。此外,从事非卫生领域工作的天主教修女更有可能不进行 BCS,COR 值为 1.71(95%,1.07-2.74)。同样,对自我乳房检查有负面接受度的天主教修女也更有可能不进行 BCS,其 AOR 为 1.65(95% CI,1.07-2.55)。结论一项研究发现,天主教修女对乳腺癌筛查的接受度较低。这凸显了在宗教团体中开展乳房健康干预计划的必要性,以消除误解并促进早期检测。
{"title":"Factors Associated With Uptake of Breast Cancer Screening Among Catholic Nuns in Lake Zone, Tanzania.","authors":"Gotfrida Marandu, Rose Laisser, Kija Malale, Peter Rambau","doi":"10.1155/2024/5024392","DOIUrl":"10.1155/2024/5024392","url":null,"abstract":"<p><p><b>Background:</b> Breast cancer is the most common cancer among women worldwide. Breast cancer screening programs are widely promoted because of their effectiveness in the early detection of cancer. However, a significant proportion of eligible Catholic nuns in the Lake Zone of Tanzania remain underscreened. This study is aimed at investigating the factors associated with breast cancer screening uptake among Catholic nuns in Lake Zone, Tanzania. <b>Methods:</b> This was a cross-sectional study design among 385 catholic nuns. Simple random sampling was deployed to enrolled catholic nuns, the ODK collect v2023.2.4 was electronically used to collect data. Binary logistic regression was used to assess the factors associated with the uptake of breast cancer screening. Statistical analysis was performed using STATA 18.0, with a significance level set at a <i>p</i> value less than 0.05. <b>Result:</b> The prevalence uptake of breast cancer screening (i.e., breast self-examination, clinical examination, or mammography examination) was 64% (<i>n</i> = 247, 95% CI, 59.3%-68.9%). A total of 57.4% had inadequate knowledge on the uptake of breast cancer screening (<i>n</i> = 221, 95% CI, 52.4%-62.4%). Also, the study found that 61.3% (95% CI, 56.4%-66.2%) of Catholic Nuns have negative attitudes towards the uptake of self-breast examination among Catholic nuns. The findings revealed that 55.6% (<i>n</i> = 133, 95% CI, 50.6%-60.6%) and 52.7% (<i>n</i> = 52.7%, 95% CI, 47.7%-57.7%) of Catholic nuns negatively accept breast cancer screening and self-breast examination, respectively. Nuns aged above 60 years were less likely to not perform BCS with a COR of 0.62 (95% CI, 0.39-0.97). Also, Catholic nuns who are in the nonhealth field are more likely to not perform BCS with a COR of 1.71 (95%, 1.07-2.74). Likewise, Catholic nuns who had negative acceptability of the Self-breast examination were more likely to not perform BCS with an AOR of 1.65 (95% CI, 1.07-2.55). <b>Conclusion:</b> A study found a low uptake of breast cancer screening among Catholic nuns. This highlights the need for breast health intervention programs within religious congregations to address misconceptions and promote early detection.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"5024392"},"PeriodicalIF":1.6,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond. 三阴性乳腺癌:肿瘤免疫原性及其他
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI: 10.1155/2024/2097920
Elio Ibrahim, Ernest Diab, Rony Hayek, Karim Hoyek, Hampig Kourie

Triple-negative breast cancer (TNBC) is a breast malignancy with a poor prognosis and limited therapeutic options. Many studies show that TNBC exhibits heterogeneity across clinical, histopathological, and molecular levels. In this review, we discuss the immunogenic features of TNBC with a focus on immunotherapy and the current standard of care in the neoadjuvant, adjuvant, and metastatic setting. In addition, we address the ongoing research on immunotherapy, antibody-drug conjugates (ADCs), poly ADP-ribose polymerase (PARP) inhibitors, and future challenges in the treatment of this entity.

三阴性乳腺癌(TNBC)是一种预后不良、治疗方案有限的乳腺恶性肿瘤。许多研究表明,TNBC 在临床、组织病理学和分子水平上表现出异质性。在这篇综述中,我们将讨论 TNBC 的免疫原性特征,重点是新辅助治疗、辅助治疗和转移性治疗中的免疫疗法和现行治疗标准。此外,我们还讨论了免疫疗法、抗体药物共轭物 (ADC)、多聚 ADP 核糖聚合酶 (PARP) 抑制剂等方面正在进行的研究,以及治疗该疾病的未来挑战。
{"title":"Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond.","authors":"Elio Ibrahim, Ernest Diab, Rony Hayek, Karim Hoyek, Hampig Kourie","doi":"10.1155/2024/2097920","DOIUrl":"https://doi.org/10.1155/2024/2097920","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is a breast malignancy with a poor prognosis and limited therapeutic options. Many studies show that TNBC exhibits heterogeneity across clinical, histopathological, and molecular levels. In this review, we discuss the immunogenic features of TNBC with a focus on immunotherapy and the current standard of care in the neoadjuvant, adjuvant, and metastatic setting. In addition, we address the ongoing research on immunotherapy, antibody-drug conjugates (ADCs), poly ADP-ribose polymerase (PARP) inhibitors, and future challenges in the treatment of this entity.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"2097920"},"PeriodicalIF":1.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing Awareness, Attitude, and Practices of Breast Cancer Screening and Prevention Among General Public and Physicians in Pakistan: A Nation With the Highest Breast Cancer Incidence in Asia. 评估巴基斯坦公众和医生对乳腺癌筛查和预防的认识、态度和做法:亚洲乳腺癌发病率最高的国家。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-09-28 eCollection Date: 2024-01-01 DOI: 10.1155/2024/2128388
Adeel Aslam, Asma Ghulam Mustafa, Ali Hussnain, Hafsa Saeed, Fatima Nazar, Maha Amjad, Ayesha Mahmood, Atika Afzal, Anam Fatima, Doaa Kamal Alkhalidi

Introduction: Breast cancer is a global health challenge with significant mortality, affecting millions worldwide. The current study is aimed at evaluating awareness and practices related to breast cancer screening, prevention, and treatment among the general public and physicians in Lahore, Pakistan, which has a significant incidence of breast cancer. Methodology: The current study adopted a cross-sectional study design conducted in Lahore, Pakistan, between March and August 2023, among 404 participants from the general public and 240 physicians. Data collection and evaluation involved the use of validated questionnaires, and both descriptive and inferential statistics were performed using SPSS Version 25. Result: In Lahore, Pakistan, breast cancer awareness among the public was low, with 80.2% unaware of its global prevalence, 65.3% believing not everyone is at risk, and only 42.1% recognizing symptoms. Females showed greater awareness (OR: 1.020, CI: 0.617-1.686, p = 0.002) and positive attitudes (OR: 2.711, CI: 1.478-6.478, p = 0.045), while the 18-29 age group had higher odds of positive practices (OR: 4.317, CI: 2.678-5.956, p = 0.004). Educational attainment significantly influences knowledge and attitudes. Only 13.9% practiced self-examination. Among physicians, 88.8% were confident in screenings, but patient fear (42.9%) and financial barriers (79.2%) hindered action. Physicians with FCPS qualifications had higher odds of awareness (OR: 1.550, CI: 1.130-2.117, p = 0.007), attitudes (OR: 1.500, CI: 1.050-2.150, p = 0.025), and practices (OR: 1.470, CI: 1.070-2.017, p = 0.020). Those with 11-20 years of experience also showed better awareness (OR: 1.400, CI: 1.050-1.868, p = 0.022) and attitudes (OR: 1.450, CI: 1.045-2.018, p = 0.029). Conclusion: In conclusion, breast cancer awareness among the general public is limited, highlighting the need for tailored education programs. Although most physicians show high awareness, challenges in patient communication and barriers, such as fear and financial constraints, must be addressed to improve screening uptake. These findings emphasize the importance of targeted interventions to enhance public awareness, screening practices, and physician-patient communication.

引言乳腺癌是一项全球性的健康挑战,死亡率很高,影响着全球数百万人。巴基斯坦拉合尔是乳腺癌的高发区,本研究旨在评估当地公众和医生对乳腺癌筛查、预防和治疗的认识和做法。研究方法:本研究采用横断面研究设计,于 2023 年 3 月至 8 月期间在巴基斯坦拉合尔进行,共有 404 名公众和 240 名医生参加。数据收集和评估使用了经过验证的调查问卷,并使用 SPSS Version 25 进行了描述性和推论性统计。结果在巴基斯坦拉合尔,公众对乳腺癌的认知度较低,80.2%的人不知道乳腺癌在全球的发病率,65.3%的人认为并非人人都有患病风险,只有 42.1%的人认识到乳腺癌的症状。女性表现出更高的认知度(OR:1.020,CI:0.617-1.686,p = 0.002)和积极的态度(OR:2.711,CI:1.478-6.478,p = 0.045),而 18-29 岁年龄组的积极实践几率更高(OR:4.317,CI:2.678-5.956,p = 0.004)。受教育程度对知识和态度有很大影响。只有 13.9% 的人进行了自我检查。在医生中,88.8%的人对筛查有信心,但病人的恐惧(42.9%)和经济障碍(79.2%)阻碍了他们的行动。具有 FCPS 资格的医生在认识(OR:1.550,CI:1.130-2.117,P = 0.007)、态度(OR:1.500,CI:1.050-2.150,P = 0.025)和实践(OR:1.470,CI:1.070-2.017,P = 0.020)方面的几率更高。拥有 11-20 年工作经验的人也表现出更好的意识(OR:1.400,CI:1.050-1.868,p = 0.022)和态度(OR:1.450,CI:1.045-2.018,p = 0.029)。结论总之,公众对乳腺癌的认识有限,这凸显了制定有针对性的教育计划的必要性。虽然大多数医生对乳腺癌有较高的认识,但要提高乳腺癌筛查率,必须解决与患者沟通方面的挑战和障碍,如恐惧和经济限制。这些发现强调了有针对性的干预措施对提高公众意识、筛查实践和医患沟通的重要性。
{"title":"Assessing Awareness, Attitude, and Practices of Breast Cancer Screening and Prevention Among General Public and Physicians in Pakistan: A Nation With the Highest Breast Cancer Incidence in Asia.","authors":"Adeel Aslam, Asma Ghulam Mustafa, Ali Hussnain, Hafsa Saeed, Fatima Nazar, Maha Amjad, Ayesha Mahmood, Atika Afzal, Anam Fatima, Doaa Kamal Alkhalidi","doi":"10.1155/2024/2128388","DOIUrl":"10.1155/2024/2128388","url":null,"abstract":"<p><p><b>Introduction:</b> Breast cancer is a global health challenge with significant mortality, affecting millions worldwide. The current study is aimed at evaluating awareness and practices related to breast cancer screening, prevention, and treatment among the general public and physicians in Lahore, Pakistan, which has a significant incidence of breast cancer. <b>Methodology:</b> The current study adopted a cross-sectional study design conducted in Lahore, Pakistan, between March and August 2023, among 404 participants from the general public and 240 physicians. Data collection and evaluation involved the use of validated questionnaires, and both descriptive and inferential statistics were performed using SPSS Version 25. <b>Result:</b> In Lahore, Pakistan, breast cancer awareness among the public was low, with 80.2% unaware of its global prevalence, 65.3% believing not everyone is at risk, and only 42.1% recognizing symptoms. Females showed greater awareness (OR: 1.020, CI: 0.617-1.686, <i>p</i> = 0.002) and positive attitudes (OR: 2.711, CI: 1.478-6.478, <i>p</i> = 0.045), while the 18-29 age group had higher odds of positive practices (OR: 4.317, CI: 2.678-5.956, <i>p</i> = 0.004). Educational attainment significantly influences knowledge and attitudes. Only 13.9% practiced self-examination. Among physicians, 88.8% were confident in screenings, but patient fear (42.9%) and financial barriers (79.2%) hindered action. Physicians with FCPS qualifications had higher odds of awareness (OR: 1.550, CI: 1.130-2.117, <i>p</i> = 0.007), attitudes (OR: 1.500, CI: 1.050-2.150, <i>p</i> = 0.025), and practices (OR: 1.470, CI: 1.070-2.017, <i>p</i> = 0.020). Those with 11-20 years of experience also showed better awareness (OR: 1.400, CI: 1.050-1.868, <i>p</i> = 0.022) and attitudes (OR: 1.450, CI: 1.045-2.018, <i>p</i> = 0.029). <b>Conclusion:</b> In conclusion, breast cancer awareness among the general public is limited, highlighting the need for tailored education programs. Although most physicians show high awareness, challenges in patient communication and barriers, such as fear and financial constraints, must be addressed to improve screening uptake. These findings emphasize the importance of targeted interventions to enhance public awareness, screening practices, and physician-patient communication.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"2128388"},"PeriodicalIF":1.6,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Tissue Eosinophilic Infiltration in Invasive Mammary Carcinoma. 浸润性乳腺癌组织嗜酸性粒细胞浸润评估
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-09-11 eCollection Date: 2024-01-01 DOI: 10.1155/2024/1514147
Farah Falah Hasan, Mohammed Haider Fadhil, Zainab Khalid Almukhtar

Background: Stromal inflammatory cells in malignant tissue have recently gained increasing interest. Unlike the extensive research on tumor-infiltrating lymphocytes, published data about tumor-infiltrating eosinophils in breast cancer are scarce. Furthermore, similar studies have yet to be conducted in Iraq. Aims: The objective of this study is to examine the presence of eosinophilic infiltration by direct visualization using light microscopy and to analyze its relationship with other histological parameters in a group of Iraqi women diagnosed with invasive mammary cancer. Methods and material: A retrospective study enrolled 90 histological samples of invasive mammary carcinoma provided by core needle biopsy from a single center, together with their immunohistochemical results for ER and HER2-NEU. Data reviewing, direct morphological visualizations, and counting eosinophilic infiltration in tissue sections were done by two independent pathologists using light microscopy. The results were statistically correlated with the grade, ER, HER2-NEU, calcification, and axillary lymph node status at presentation. Results: Out of the entire sample size (90), 40 (44%) showed the presence of eosinophilic infiltration in the tissue, both intratumoral and stromal. Further analysis revealed that most eosinophilic infiltrates had an intermediate score (4-19) per 10 consecutive high-power fields. A strong and meaningful statistical relationship was seen between tissue eosinophilic infiltration and HER2/NEU status. A statistically insignificant correlation was seen between tissue eosinophilic infiltration and histological grade, ER receptor status, calcification, and axillary lymph node status at presentation. Conclusions: Eosinophils are tumor-infiltrating cells in breast cancer, both intratumoral and stromal. The presence of tissue eosinophilic infiltration can predict HER2/NEU negativity in breast cancer.

背景:恶性肿瘤组织中的基质炎性细胞最近越来越受到关注。与对肿瘤浸润淋巴细胞的广泛研究不同,有关乳腺癌中肿瘤浸润嗜酸性粒细胞的已发表数据很少。此外,类似的研究在伊拉克也尚未开展。目的:本研究的目的是通过光镜直接观察嗜酸性粒细胞浸润的存在,并分析一组被诊断为浸润性乳腺癌的伊拉克妇女中嗜酸性粒细胞浸润与其他组织学参数的关系。方法和材料:一项回顾性研究收集了一个中心通过核心针活检提供的 90 份浸润性乳腺癌组织学样本,以及这些样本的 ER 和 HER2-NEU 免疫组化结果。数据审核、直接形态学观察和组织切片中嗜酸性粒细胞浸润计数由两名独立病理学家使用光学显微镜完成。结果与患者发病时的分级、ER、HER2-NEU、钙化和腋窝淋巴结状态相关。结果在所有样本(90 例)中,有 40 例(44%)的组织出现了嗜酸性粒细胞浸润,包括瘤内和基质。进一步分析表明,大多数嗜酸性粒细胞浸润在每 10 个连续高倍视野中得分中等(4-19 分)。组织嗜酸性粒细胞浸润与 HER2/NEU 状态之间存在密切而有意义的统计学关系。组织嗜酸性粒细胞浸润与组织学分级、ER受体状态、钙化和发病时的腋窝淋巴结状态之间的相关性在统计学上并不显著。结论嗜酸性粒细胞是乳腺癌的肿瘤浸润细胞,包括瘤内细胞和基质细胞。组织嗜酸性粒细胞浸润的存在可预测乳腺癌的 HER2/NEU 阴性。
{"title":"Assessment of Tissue Eosinophilic Infiltration in Invasive Mammary Carcinoma.","authors":"Farah Falah Hasan, Mohammed Haider Fadhil, Zainab Khalid Almukhtar","doi":"10.1155/2024/1514147","DOIUrl":"https://doi.org/10.1155/2024/1514147","url":null,"abstract":"<p><p><b>Background:</b> Stromal inflammatory cells in malignant tissue have recently gained increasing interest. Unlike the extensive research on tumor-infiltrating lymphocytes, published data about tumor-infiltrating eosinophils in breast cancer are scarce. Furthermore, similar studies have yet to be conducted in Iraq. <b>Aims</b>: The objective of this study is to examine the presence of eosinophilic infiltration by direct visualization using light microscopy and to analyze its relationship with other histological parameters in a group of Iraqi women diagnosed with invasive mammary cancer. <b>Methods and material</b>: A retrospective study enrolled 90 histological samples of invasive mammary carcinoma provided by core needle biopsy from a single center, together with their immunohistochemical results for ER and HER2-NEU. Data reviewing, direct morphological visualizations, and counting eosinophilic infiltration in tissue sections were done by two independent pathologists using light microscopy. The results were statistically correlated with the grade, ER, HER2-NEU, calcification, and axillary lymph node status at presentation. <b>Results</b>: Out of the entire sample size (90), 40 (44%) showed the presence of eosinophilic infiltration in the tissue, both intratumoral and stromal. Further analysis revealed that most eosinophilic infiltrates had an intermediate score (4-19) per 10 consecutive high-power fields. A strong and meaningful statistical relationship was seen between tissue eosinophilic infiltration and HER2/NEU status. A statistically insignificant correlation was seen between tissue eosinophilic infiltration and histological grade, ER receptor status, calcification, and axillary lymph node status at presentation. <b>Conclusions</b>: Eosinophils are tumor-infiltrating cells in breast cancer, both intratumoral and stromal. The presence of tissue eosinophilic infiltration can predict HER2/NEU negativity in breast cancer.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"1514147"},"PeriodicalIF":1.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metformin as a Potential In Vitro Anticancer Modulator of Adenosine Monophosphate Kinase: A Review. 二甲双胍作为单磷酸腺苷激酶的潜在体外抗癌调节剂:综述。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-08-27 eCollection Date: 2024-01-01 DOI: 10.1155/2024/1094274
A G R Greshamali Jinadasa, H M Kasuni Akalanka, N D Amal Wageesha, Sagarika Ekanayake

Metformin (MET) is the commonly prescribed hypoglycemic agent used in the treatment of type 2 diabetes mellitus (DM). Pleiotropic effects of MET are emerging as a medication for other diseases including breast cancer (BC). Therefore, a literature review was conducted to investigate whether the anticancer effects of MET are mediated through adenosine monophosphate kinase (AMPK). This review assessed published data focusing on studies where BC cell lines were treated with MET to explore its potential anticancer effects via AMPK on BC cells. The published data reveals that activated AMPK induces anticancer effects primarily by suppressing cell proliferation, induction of apoptosis, and cell cycle arrest, inhibition of metastasis and invasion, alteration of tumor microenvironment, and downregulation of tumorigenesis. In addition, MET was observed to induce AMPK-mediated effects when combined with other drugs. Further studies on assessing the potential use of MET alone or in combination with other drugs would pave the way to design new treatment strategies for BC.

二甲双胍(MET)是治疗 2 型糖尿病(DM)的常用降糖药。二甲双胍作为一种治疗包括乳腺癌(BC)在内的其他疾病的药物,其多效应正在显现。因此,我们进行了一项文献综述,以研究 MET 的抗癌作用是否通过单磷酸腺苷激酶 (AMPK) 介导。本综述评估了已发表的数据,重点关注用 MET 处理 BC 细胞系的研究,以探索 MET 通过 AMPK 对 BC 细胞的潜在抗癌作用。已发表的数据显示,活化的 AMPK 主要通过抑制细胞增殖、诱导细胞凋亡和细胞周期停滞、抑制转移和侵袭、改变肿瘤微环境以及下调肿瘤发生来诱导抗癌作用。此外,还观察到 MET 与其他药物联用时可诱导 AMPK 介导的效应。进一步研究评估 MET 单独使用或与其他药物联合使用的潜力,将为设计新的 BC 治疗策略铺平道路。
{"title":"Metformin as a Potential <i>In Vitro</i> Anticancer Modulator of Adenosine Monophosphate Kinase: A Review.","authors":"A G R Greshamali Jinadasa, H M Kasuni Akalanka, N D Amal Wageesha, Sagarika Ekanayake","doi":"10.1155/2024/1094274","DOIUrl":"10.1155/2024/1094274","url":null,"abstract":"<p><p>Metformin (MET) is the commonly prescribed hypoglycemic agent used in the treatment of type 2 diabetes mellitus (DM). Pleiotropic effects of MET are emerging as a medication for other diseases including breast cancer (BC). Therefore, a literature review was conducted to investigate whether the anticancer effects of MET are mediated through adenosine monophosphate kinase (AMPK). This review assessed published data focusing on studies where BC cell lines were treated with MET to explore its potential anticancer effects via AMPK on BC cells. The published data reveals that activated AMPK induces anticancer effects primarily by suppressing cell proliferation, induction of apoptosis, and cell cycle arrest, inhibition of metastasis and invasion, alteration of tumor microenvironment, and downregulation of tumorigenesis. In addition, MET was observed to induce AMPK-mediated effects when combined with other drugs. Further studies on assessing the potential use of MET alone or in combination with other drugs would pave the way to design new treatment strategies for BC.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"1094274"},"PeriodicalIF":1.6,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Breast Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1